Medtronic
Medical technology group behind the Hugo robotic-assisted surgery system
- Intuitive places 468 da Vinci robots as upgrades to da Vinci 5 accelerate, and raises its margin outlook for a second time
Intuitive placed 468 da Vinci systems in the second quarter of 2026, up from 395 a year earlier, including 246 da Vinci 5 units, and revenue rose 19% to $2.89 billion, the company said on 16 July. It lifted its 2026 non-GAAP gross margin outlook to 68% to 69% of revenue, the second increase this year, while holding da Vinci procedure growth guidance at 13.5% to 15.5% and pointing to the midpoint.
Mentioned - MicroPort MedBot doubles revenue to RMB551 million as Toumai exports reach 73% of 2025 sales
Shanghai MicroPort MedBot said revenue rose 114.2% to RMB551.1 million in 2025, with overseas sales of RMB400.2 million accounting for 73% of the total. The Hong Kong-listed surgical robot maker cut its net loss by 60.7% to RMB254.1 million as cumulative orders for its Toumai laparoscopic robot reached about 220 units.
Mentioned - Intuitive passes $10 billion in revenue as da Vinci 5 takes half of its robot shipments, but guides procedure growth lower
Intuitive reported on January 22, 2026 that 2025 revenue rose about 21% to $10.06 billion as surgeons performed 3.153 million da Vinci procedures, and da Vinci 5 made up 870 of the 1,721 systems it placed. The company guided 2026 da Vinci procedure growth to 13% to 15%, down from about 18%, and put the tariff cost to its gross margin at about 1.2% of revenue.
Mentioned - Edge Medical lists in Hong Kong after retail demand of 1,092 times, betting its surgical robots on export markets
Shenzhen Edge Medical raised HK$1,198.7 million in a Hong Kong IPO priced at HK$43.24 a share and began trading on 8 January 2026, with the retail tranche 1,091.94 times subscribed. Its first annual results showed revenue up 184.8% to RMB455.7 million and 50 of 72 robots delivered in 2025 going overseas.
Mentioned - Johnson & Johnson files Ottava surgical robot with the FDA, seeking a De Novo route into general surgery
Johnson & Johnson has submitted its Ottava soft-tissue surgical robot to the US Food and Drug Administration in a De Novo classification request covering several upper abdominal procedures, backed by a 32-patient gastric bypass study at six US hospitals. The filing comes weeks after Medtronic and CMR Surgical won US clearances, widening the field challenging Intuitive's 10,763-system da Vinci base.
Mentioned - Medtronic wins FDA clearance for its Hugo surgical robot in urology, opening a US challenge to Intuitive's 10,763 da Vinci systems
The FDA cleared Medtronic's Hugo robotic-assisted surgery system for prostatectomy, nephrectomy and cystectomy on December 3, 2025, after a 268-day 510(k) review. The clearance rests on the 137-patient Expand URO study, which reported a 98.5% surgical success rate, and gives Medtronic its first US entry against Intuitive's da Vinci after years of selling Hugo in more than 30 other countries.
Subject - Distalmotion raises US$150 million to take its DEXTER surgical robot into US outpatient centres
Swiss surgical robot maker Distalmotion closed a US$150 million Series G led by Revival Healthcare Capital on 18 November 2025 and named former Silk Road Medical chief executive Chas McKhann executive chairman. Johnson & Johnson's venture arm followed with a strategic investment in January 2026, and by August the FDA had cleared DEXTER for five procedures aimed at ambulatory surgery centres.
Mentioned - NVIDIA puts a Blackwell brain inside robots with the $3,499 Jetson Thor as Figure, Agility and Boston Dynamics sign on
NVIDIA made its Jetson AGX Thor developer kit and Jetson T5000 production modules generally available on 25 August 2025, pricing the kit from $3,499 and claiming 7.5 times the AI compute of Jetson Orin with 128 GB of memory. Figure, Agility Robotics, Boston Dynamics and Amazon Robotics are among eight named early adopters, while 1X, OpenAI and Physical Intelligence are evaluating the computer.
Partner